Indomethacin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Indomethacin: From Inflammatory & Pain Conditions to Brachydactyly-Syndactyly Syndrome
One-Sentence Summary
Indomethacin is a classic non-selective NSAID historically used for inflammatory and pain-related conditions. The TxGNN model predicts it may be effective for brachydactyly-syndactyly syndrome, a rare congenital limb malformation syndrome, but this prediction is currently supported by 0 clinical trials and 0 publications — the evidence pack itself flags it as a purely model-driven signal with no known mechanistic basis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in this evidence pack (indomethacin is a well-established NSAID; formal indication text was not provided) |
| Predicted New Indication | Brachydactyly-syndactyly syndrome |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Mechanism of action data for indomethacin was not included in this evidence pack. Based on general pharmacological knowledge, indomethacin is a non-selective COX-1/COX-2 inhibitor NSAID, historically applied across a range of inflammatory and pain-related conditions.
Brachydactyly-syndactyly syndrome, however, is a rare congenital limb malformation disorder driven by structural/developmental genetic pathology rather than an inflammatory process. The evidence pack’s own mechanistic assessment states explicitly that there is no known association between indomethacin’s anti-inflammatory mechanism and this disease’s pathophysiology.
As a result, this candidate should be interpreted with caution: a very high TxGNN score alone does not establish biological plausibility. No supporting mechanism, clinical trial, or literature evidence exists in this pack for this specific drug–disease pair — the association is purely model-derived (rank 1411 in the underlying prediction set).
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- No clinical trial, literature, or mechanistic evidence supports indomethacin for brachydactyly-syndactyly syndrome; the TxGNN score reflects a model-only association (L5, decision stage S0), which does not meet the bar for further evaluation.
To proceed, the following is needed:
- Independent preclinical or mechanistic data linking COX inhibition to brachydactyly-syndactyly pathophysiology, if this candidate is to be pursued further
- Indomethacin’s original approved indication text and MOA data (both absent from this evidence pack)
- Note: a separate candidate in this same evidence pack, juvenile idiopathic arthritis (rank 8, evidence level L3, “Proceed with Guardrails”), is supported by 20 literature references including a double-blind RCT (PMID 362571) and reflects indomethacin’s well-established historical off-label use in pediatric rheumatic disease — this may be a more actionable direction to evaluate in parallel.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.